BMS's Cobenfy faces market hurdles as side effects limit uptake, MapLight eyes opportunity
The FDA approved Bristol Myers Squibb's Cobenfy in 2024, marking the first novel schizophrenia treatment in 35 years and raising hopes for a new therapeutic approach.
Since its launch, the drug has struggled to gain market traction. BMS officials cite a side‑effect profile that includes pro‑cholinergic gastrointestinal symptoms, which have tempered clinician and patient enthusiasm.
MapLight Therapeutics, led by CEO Christopher Kroeger, sees the challenges with Cobenfy as an opening for its own pipeline, suggesting competitive pressure may intensify in the schizophrenia space.
The situation highlights the difficulty of translating regulatory approval into commercial success for new neuropsychiatric agents.
This writeup was produced by pharmadog from original reporting by BioSpace.
Original headline: “As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door”
read at BioSpace ↗
comments(0)
5-min edit window · permanent after that